Star Equity Holdings, Inc.
Star Equity Holdings, Inc. (STRR) Stock Competitors & Peer Comparison
See (STRR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STRR | $9.45 | +1.61% | 35.3M | -4.57 | -$2.08 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.77% |
| TMO | $469.71 | +0.64% | 174.5B | 25.80 | $18.20 | +0.38% |
| DHR | $177.25 | -0.74% | 125.4B | 34.35 | $5.16 | +0.77% |
| IDXX | $565.93 | +0.89% | 45.1B | 43.33 | $13.06 | N/A |
| A | $115.55 | +0.99% | 32.6B | 25.50 | $4.53 | +0.87% |
| NTRA | $203.75 | +1.30% | 28.9B | -134.05 | -$1.52 | N/A |
| IQV | $162.28 | +1.00% | 27.5B | 20.73 | $7.83 | N/A |
| MTD | $1,282.45 | +1.43% | 26.1B | 30.45 | $42.09 | N/A |
| LH | $263.80 | -0.42% | 21.7B | 25.19 | $10.47 | +1.09% |
Stock Comparison
STRR vs DHR-PB Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, STRR is priced at $9.45, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, STRR's ROE is -0.10%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, STRR is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check DHR-PB's competition here
STRR vs TMO Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, TMO has a market cap of 174.5B. Regarding current trading prices, STRR is priced at $9.45, while TMO trades at $469.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas TMO's P/E ratio is 25.80. In terms of profitability, STRR's ROE is -0.10%, compared to TMO's ROE of +0.13%. Regarding short-term risk, STRR is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check TMO's competition here
STRR vs DHR Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, DHR has a market cap of 125.4B. Regarding current trading prices, STRR is priced at $9.45, while DHR trades at $177.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas DHR's P/E ratio is 34.35. In terms of profitability, STRR's ROE is -0.10%, compared to DHR's ROE of +0.07%. Regarding short-term risk, STRR is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check DHR's competition here
STRR vs IDXX Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, IDXX has a market cap of 45.1B. Regarding current trading prices, STRR is priced at $9.45, while IDXX trades at $565.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas IDXX's P/E ratio is 43.33. In terms of profitability, STRR's ROE is -0.10%, compared to IDXX's ROE of +0.70%. Regarding short-term risk, STRR is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check IDXX's competition here
STRR vs A Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, A has a market cap of 32.6B. Regarding current trading prices, STRR is priced at $9.45, while A trades at $115.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas A's P/E ratio is 25.50. In terms of profitability, STRR's ROE is -0.10%, compared to A's ROE of +0.20%. Regarding short-term risk, STRR is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check A's competition here
STRR vs NTRA Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, NTRA has a market cap of 28.9B. Regarding current trading prices, STRR is priced at $9.45, while NTRA trades at $203.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas NTRA's P/E ratio is -134.05. In terms of profitability, STRR's ROE is -0.10%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, STRR is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NTRA's competition here
STRR vs IQV Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, IQV has a market cap of 27.5B. Regarding current trading prices, STRR is priced at $9.45, while IQV trades at $162.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas IQV's P/E ratio is 20.73. In terms of profitability, STRR's ROE is -0.10%, compared to IQV's ROE of +0.22%. Regarding short-term risk, STRR is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check IQV's competition here
STRR vs MTD Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, MTD has a market cap of 26.1B. Regarding current trading prices, STRR is priced at $9.45, while MTD trades at $1,282.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas MTD's P/E ratio is 30.45. In terms of profitability, STRR's ROE is -0.10%, compared to MTD's ROE of -4.87%. Regarding short-term risk, STRR is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MTD's competition here
STRR vs LH Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, LH has a market cap of 21.7B. Regarding current trading prices, STRR is priced at $9.45, while LH trades at $263.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas LH's P/E ratio is 25.19. In terms of profitability, STRR's ROE is -0.10%, compared to LH's ROE of +0.10%. Regarding short-term risk, STRR is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check LH's competition here
STRR vs DGX Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, DGX has a market cap of 21.7B. Regarding current trading prices, STRR is priced at $9.45, while DGX trades at $196.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas DGX's P/E ratio is 21.66. In terms of profitability, STRR's ROE is -0.10%, compared to DGX's ROE of +0.14%. Regarding short-term risk, STRR is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check DGX's competition here
STRR vs EXAS Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, STRR is priced at $9.45, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas EXAS's P/E ratio is -95.37. In terms of profitability, STRR's ROE is -0.10%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, STRR is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check EXAS's competition here
STRR vs ILMN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ILMN has a market cap of 19.6B. Regarding current trading prices, STRR is priced at $9.45, while ILMN trades at $127.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ILMN's P/E ratio is 23.46. In terms of profitability, STRR's ROE is -0.10%, compared to ILMN's ROE of +0.35%. Regarding short-term risk, STRR is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ILMN's competition here
STRR vs WAT Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, WAT has a market cap of 18.4B. Regarding current trading prices, STRR is priced at $9.45, while WAT trades at $309.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas WAT's P/E ratio is 28.76. In terms of profitability, STRR's ROE is -0.10%, compared to WAT's ROE of +0.29%. Regarding short-term risk, STRR is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check WAT's competition here
STRR vs PKI Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, STRR is priced at $9.45, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas PKI's P/E ratio is 41.45. In terms of profitability, STRR's ROE is -0.10%, compared to PKI's ROE of +0.03%. Regarding short-term risk, STRR is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check PKI's competition here
STRR vs MEDP Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, MEDP has a market cap of 11.7B. Regarding current trading prices, STRR is priced at $9.45, while MEDP trades at $410.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas MEDP's P/E ratio is 26.90. In terms of profitability, STRR's ROE is -0.10%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, STRR is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MEDP's competition here
STRR vs GH Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, GH has a market cap of 11.7B. Regarding current trading prices, STRR is priced at $9.45, while GH trades at $88.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas GH's P/E ratio is -26.78. In terms of profitability, STRR's ROE is -0.10%, compared to GH's ROE of +1.65%. Regarding short-term risk, STRR is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check GH's competition here
STRR vs RVTY Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, RVTY has a market cap of 9.7B. Regarding current trading prices, STRR is priced at $9.45, while RVTY trades at $86.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas RVTY's P/E ratio is 42.12. In terms of profitability, STRR's ROE is -0.10%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, STRR is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check RVTY's competition here
STRR vs CRL Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CRL has a market cap of 8.4B. Regarding current trading prices, STRR is priced at $9.45, while CRL trades at $169.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CRL's P/E ratio is -58.37. In terms of profitability, STRR's ROE is -0.10%, compared to CRL's ROE of -0.04%. Regarding short-term risk, STRR is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check CRL's competition here
STRR vs QGEN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, QGEN has a market cap of 7.9B. Regarding current trading prices, STRR is priced at $9.45, while QGEN trades at $38.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas QGEN's P/E ratio is 18.82. In terms of profitability, STRR's ROE is -0.10%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, STRR is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check QGEN's competition here
STRR vs ICLR Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ICLR has a market cap of 7.8B. Regarding current trading prices, STRR is priced at $9.45, while ICLR trades at $102.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ICLR's P/E ratio is 13.77. In terms of profitability, STRR's ROE is -0.10%, compared to ICLR's ROE of +0.06%. Regarding short-term risk, STRR is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ICLR's competition here
STRR vs RDNT Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, RDNT has a market cap of 4.5B. Regarding current trading prices, STRR is priced at $9.45, while RDNT trades at $57.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas RDNT's P/E ratio is -230.60. In terms of profitability, STRR's ROE is -0.10%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, STRR is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check RDNT's competition here
STRR vs SYNH Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, STRR is priced at $9.45, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas SYNH's P/E ratio is 61.40. In terms of profitability, STRR's ROE is -0.10%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, STRR is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check SYNH's competition here
STRR vs SHC Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, SHC has a market cap of 4.4B. Regarding current trading prices, STRR is priced at $9.45, while SHC trades at $15.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas SHC's P/E ratio is 57.70. In terms of profitability, STRR's ROE is -0.10%, compared to SHC's ROE of +0.15%. Regarding short-term risk, STRR is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check SHC's competition here
STRR vs BLLN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BLLN has a market cap of 3.9B. Regarding current trading prices, STRR is priced at $9.45, while BLLN trades at $84.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BLLN's P/E ratio is 605.29. In terms of profitability, STRR's ROE is -0.10%, compared to BLLN's ROE of +0.01%. Regarding short-term risk, STRR is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BLLN's competition here
STRR vs TWST Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, TWST has a market cap of 3.7B. Regarding current trading prices, STRR is priced at $9.45, while TWST trades at $60.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas TWST's P/E ratio is -47.98. In terms of profitability, STRR's ROE is -0.10%, compared to TWST's ROE of -0.17%. Regarding short-term risk, STRR is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check TWST's competition here
STRR vs OLK Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, STRR is priced at $9.45, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas OLK's P/E ratio is -96.59. In terms of profitability, STRR's ROE is -0.10%, compared to OLK's ROE of -0.07%. Regarding short-term risk, STRR is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check OLK's competition here
STRR vs GRAL Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, GRAL has a market cap of 2.2B. Regarding current trading prices, STRR is priced at $9.45, while GRAL trades at $54.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas GRAL's P/E ratio is -4.90. In terms of profitability, STRR's ROE is -0.10%, compared to GRAL's ROE of -0.17%. Regarding short-term risk, STRR is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check GRAL's competition here
STRR vs NEOG Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, NEOG has a market cap of 2.1B. Regarding current trading prices, STRR is priced at $9.45, while NEOG trades at $9.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas NEOG's P/E ratio is -3.41. In terms of profitability, STRR's ROE is -0.10%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, STRR is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NEOG's competition here
STRR vs CDNA Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, STRR is priced at $9.45, while CDNA trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CDNA's P/E ratio is -53.07. In terms of profitability, STRR's ROE is -0.10%, compared to CDNA's ROE of -0.06%. Regarding short-term risk, STRR is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CDNA's competition here
STRR vs OPK Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, OPK has a market cap of 944.3M. Regarding current trading prices, STRR is priced at $9.45, while OPK trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas OPK's P/E ratio is -4.10. In terms of profitability, STRR's ROE is -0.10%, compared to OPK's ROE of -0.17%. Regarding short-term risk, STRR is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check OPK's competition here
STRR vs CSTL Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CSTL has a market cap of 727.2M. Regarding current trading prices, STRR is priced at $9.45, while CSTL trades at $24.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CSTL's P/E ratio is -29.47. In terms of profitability, STRR's ROE is -0.10%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, STRR is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CSTL's competition here
STRR vs GRALV Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, STRR is priced at $9.45, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas GRALV's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to GRALV's ROE of N/A. Regarding short-term risk, STRR is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check GRALV's competition here
STRR vs PSNL Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, PSNL has a market cap of 541.7M. Regarding current trading prices, STRR is priced at $9.45, while PSNL trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas PSNL's P/E ratio is -6.70. In terms of profitability, STRR's ROE is -0.10%, compared to PSNL's ROE of -0.39%. Regarding short-term risk, STRR is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check PSNL's competition here
STRR vs ACRS Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ACRS has a market cap of 518.6M. Regarding current trading prices, STRR is priced at $9.45, while ACRS trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ACRS's P/E ratio is -8.11. In terms of profitability, STRR's ROE is -0.10%, compared to ACRS's ROE of -0.52%. Regarding short-term risk, STRR is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ACRS's competition here
STRR vs FLGT Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, FLGT has a market cap of 509.4M. Regarding current trading prices, STRR is priced at $9.45, while FLGT trades at $16.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas FLGT's P/E ratio is -8.28. In terms of profitability, STRR's ROE is -0.10%, compared to FLGT's ROE of -0.05%. Regarding short-term risk, STRR is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check FLGT's competition here
STRR vs MYGN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, MYGN has a market cap of 447M. Regarding current trading prices, STRR is priced at $9.45, while MYGN trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas MYGN's P/E ratio is -1.21. In terms of profitability, STRR's ROE is -0.10%, compared to MYGN's ROE of -0.80%. Regarding short-term risk, STRR is more volatile compared to MYGN. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check MYGN's competition here
STRR vs CO Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, STRR is priced at $9.45, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CO's P/E ratio is 5.06. In terms of profitability, STRR's ROE is -0.10%, compared to CO's ROE of +0.11%. Regarding short-term risk, STRR is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CO's competition here
STRR vs FLDM Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, STRR is priced at $9.45, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas FLDM's P/E ratio is -4.74. In terms of profitability, STRR's ROE is -0.10%, compared to FLDM's ROE of -0.18%. Regarding short-term risk, STRR is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check FLDM's competition here
STRR vs PRE Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, PRE has a market cap of 257.6M. Regarding current trading prices, STRR is priced at $9.45, while PRE trades at $18.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas PRE's P/E ratio is -4.84. In terms of profitability, STRR's ROE is -0.10%, compared to PRE's ROE of -0.36%. Regarding short-term risk, STRR is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check PRE's competition here
STRR vs OPGN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, STRR is priced at $9.45, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas OPGN's P/E ratio is 132.83. In terms of profitability, STRR's ROE is -0.10%, compared to OPGN's ROE of +0.78%. Regarding short-term risk, STRR is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check OPGN's competition here
STRR vs NEO Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, NEO has a market cap of 215.2M. Regarding current trading prices, STRR is priced at $9.45, while NEO trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas NEO's P/E ratio is -9.87. In terms of profitability, STRR's ROE is -0.10%, compared to NEO's ROE of -0.13%. Regarding short-term risk, STRR is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NEO's competition here
STRR vs ATLN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ATLN has a market cap of 134.9M. Regarding current trading prices, STRR is priced at $9.45, while ATLN trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ATLN's P/E ratio is -1.57. In terms of profitability, STRR's ROE is -0.10%, compared to ATLN's ROE of +2.74%. Regarding short-term risk, STRR is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ATLN's competition here
STRR vs GTH Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, STRR is priced at $9.45, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas GTH's P/E ratio is -1.11. In terms of profitability, STRR's ROE is -0.10%, compared to GTH's ROE of -1.01%. Regarding short-term risk, STRR is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check GTH's competition here
STRR vs STIM Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, STIM has a market cap of 116.4M. Regarding current trading prices, STRR is priced at $9.45, while STIM trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas STIM's P/E ratio is -2.85. In terms of profitability, STRR's ROE is -0.10%, compared to STIM's ROE of -1.39%. Regarding short-term risk, STRR is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check STIM's competition here
STRR vs GENE Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, STRR is priced at $9.45, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas GENE's P/E ratio is -38.25. In terms of profitability, STRR's ROE is -0.10%, compared to GENE's ROE of -1.85%. Regarding short-term risk, STRR is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check GENE's competition here
STRR vs MDXH Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, MDXH has a market cap of 106.8M. Regarding current trading prices, STRR is priced at $9.45, while MDXH trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas MDXH's P/E ratio is -3.10. In terms of profitability, STRR's ROE is -0.10%, compared to MDXH's ROE of +5.17%. Regarding short-term risk, STRR is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MDXH's competition here
STRR vs BDSX Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BDSX has a market cap of 80.3M. Regarding current trading prices, STRR is priced at $9.45, while BDSX trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BDSX's P/E ratio is -2.28. In terms of profitability, STRR's ROE is -0.10%, compared to BDSX's ROE of -17.61%. Regarding short-term risk, STRR is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BDSX's competition here
STRR vs SERA Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, SERA has a market cap of 76.7M. Regarding current trading prices, STRR is priced at $9.45, while SERA trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas SERA's P/E ratio is -3.00. In terms of profitability, STRR's ROE is -0.10%, compared to SERA's ROE of -0.37%. Regarding short-term risk, STRR is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check SERA's competition here
STRR vs XGN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, XGN has a market cap of 64.9M. Regarding current trading prices, STRR is priced at $9.45, while XGN trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas XGN's P/E ratio is -2.90. In terms of profitability, STRR's ROE is -0.10%, compared to XGN's ROE of -1.27%. Regarding short-term risk, STRR is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check XGN's competition here
STRR vs DRIO Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, DRIO has a market cap of 54.1M. Regarding current trading prices, STRR is priced at $9.45, while DRIO trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas DRIO's P/E ratio is -0.73. In terms of profitability, STRR's ROE is -0.10%, compared to DRIO's ROE of +0.88%. Regarding short-term risk, STRR is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check DRIO's competition here
STRR vs PRPO Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, PRPO has a market cap of 50.4M. Regarding current trading prices, STRR is priced at $9.45, while PRPO trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas PRPO's P/E ratio is -122.74. In terms of profitability, STRR's ROE is -0.10%, compared to PRPO's ROE of -0.03%. Regarding short-term risk, STRR is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check PRPO's competition here
STRR vs STRRP Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, STRRP has a market cap of 32.3M. Regarding current trading prices, STRR is priced at $9.45, while STRRP trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas STRRP's P/E ratio is -5.06. In terms of profitability, STRR's ROE is -0.10%, compared to STRRP's ROE of -0.10%. Regarding short-term risk, STRR is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check STRRP's competition here
STRR vs AKU Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, STRR is priced at $9.45, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas AKU's P/E ratio is -0.13. In terms of profitability, STRR's ROE is -0.10%, compared to AKU's ROE of -5.32%. Regarding short-term risk, STRR is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check AKU's competition here
STRR vs BNR Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BNR has a market cap of 22.3M. Regarding current trading prices, STRR is priced at $9.45, while BNR trades at $20.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BNR's P/E ratio is -27.59. In terms of profitability, STRR's ROE is -0.10%, compared to BNR's ROE of -0.10%. Regarding short-term risk, STRR is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BNR's competition here
STRR vs CEMI Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, STRR is priced at $9.45, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CEMI's P/E ratio is -0.63. In terms of profitability, STRR's ROE is -0.10%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, STRR is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check CEMI's competition here
STRR vs ENZ Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, STRR is priced at $9.45, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ENZ's P/E ratio is -2.24. In terms of profitability, STRR's ROE is -0.10%, compared to ENZ's ROE of -0.17%. Regarding short-term risk, STRR is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ENZ's competition here
STRR vs PMD Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, STRR is priced at $9.45, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas PMD's P/E ratio is -5.24. In terms of profitability, STRR's ROE is -0.10%, compared to PMD's ROE of -0.32%. Regarding short-term risk, STRR is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check PMD's competition here
STRR vs ME Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, STRR is priced at $9.45, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ME's P/E ratio is -0.03. In terms of profitability, STRR's ROE is -0.10%, compared to ME's ROE of -7.71%. Regarding short-term risk, STRR is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check ME's competition here
STRR vs VNRX Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, VNRX has a market cap of 15.2M. Regarding current trading prices, STRR is priced at $9.45, while VNRX trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas VNRX's P/E ratio is -0.64. In terms of profitability, STRR's ROE is -0.10%, compared to VNRX's ROE of +0.73%. Regarding short-term risk, STRR is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check VNRX's competition here
STRR vs BIAF Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BIAF has a market cap of 10M. Regarding current trading prices, STRR is priced at $9.45, while BIAF trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BIAF's P/E ratio is -0.26. In terms of profitability, STRR's ROE is -0.10%, compared to BIAF's ROE of -3.85%. Regarding short-term risk, STRR is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BIAF's competition here
STRR vs CHEK Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CHEK has a market cap of 9.8M. Regarding current trading prices, STRR is priced at $9.45, while CHEK trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CHEK's P/E ratio is -0.39. In terms of profitability, STRR's ROE is -0.10%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, STRR is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CHEK's competition here
STRR vs NOTV Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, NOTV has a market cap of 9.6M. Regarding current trading prices, STRR is priced at $9.45, while NOTV trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas NOTV's P/E ratio is -0.15. In terms of profitability, STRR's ROE is -0.10%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, STRR is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NOTV's competition here
STRR vs CNTG Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, STRR is priced at $9.45, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CNTG's P/E ratio is -0.23. In terms of profitability, STRR's ROE is -0.10%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, STRR is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check CNTG's competition here
STRR vs MBAI Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, MBAI has a market cap of 8.8M. Regarding current trading prices, STRR is priced at $9.45, while MBAI trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas MBAI's P/E ratio is -0.65. In terms of profitability, STRR's ROE is -0.10%, compared to MBAI's ROE of -2.26%. Regarding short-term risk, STRR is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MBAI's competition here
STRR vs APDN Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, STRR is priced at $9.45, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas APDN's P/E ratio is -0.10. In terms of profitability, STRR's ROE is -0.10%, compared to APDN's ROE of -8.97%. Regarding short-term risk, STRR is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check APDN's competition here
STRR vs TRIB Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, TRIB has a market cap of 6.7M. Regarding current trading prices, STRR is priced at $9.45, while TRIB trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas TRIB's P/E ratio is -0.41. In terms of profitability, STRR's ROE is -0.10%, compared to TRIB's ROE of +0.81%. Regarding short-term risk, STRR is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check TRIB's competition here
STRR vs QUCY Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, QUCY has a market cap of 6.3M. Regarding current trading prices, STRR is priced at $9.45, while QUCY trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas QUCY's P/E ratio is -0.02. In terms of profitability, STRR's ROE is -0.10%, compared to QUCY's ROE of -4.66%. Regarding short-term risk, STRR is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check QUCY's competition here
STRR vs ADVB Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ADVB has a market cap of 6.2M. Regarding current trading prices, STRR is priced at $9.45, while ADVB trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ADVB's P/E ratio is 1.63. In terms of profitability, STRR's ROE is -0.10%, compared to ADVB's ROE of +1.01%. Regarding short-term risk, STRR is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ADVB's competition here
STRR vs NVTA Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, STRR is priced at $9.45, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas NVTA's P/E ratio is -0.00. In terms of profitability, STRR's ROE is -0.10%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, STRR is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NVTA's competition here
STRR vs LMDXW Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, STRR is priced at $9.45, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, STRR's ROE is -0.10%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, STRR is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check LMDXW's competition here
STRR vs LMDX Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, STRR is priced at $9.45, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas LMDX's P/E ratio is -0.01. In terms of profitability, STRR's ROE is -0.10%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, STRR is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check LMDX's competition here
STRR vs BGLC Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BGLC has a market cap of 4.1M. Regarding current trading prices, STRR is priced at $9.45, while BGLC trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BGLC's P/E ratio is -1.37. In terms of profitability, STRR's ROE is -0.10%, compared to BGLC's ROE of -0.39%. Regarding short-term risk, STRR is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check BGLC's competition here
STRR vs BNGO Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BNGO has a market cap of 4M. Regarding current trading prices, STRR is priced at $9.45, while BNGO trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BNGO's P/E ratio is -0.25. In terms of profitability, STRR's ROE is -0.10%, compared to BNGO's ROE of -0.56%. Regarding short-term risk, STRR is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BNGO's competition here
STRR vs NDRA Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, NDRA has a market cap of 3.7M. Regarding current trading prices, STRR is priced at $9.45, while NDRA trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas NDRA's P/E ratio is -0.56. In terms of profitability, STRR's ROE is -0.10%, compared to NDRA's ROE of -4.97%. Regarding short-term risk, STRR is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NDRA's competition here
STRR vs DMTK Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, STRR is priced at $9.45, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas DMTK's P/E ratio is -0.04. In terms of profitability, STRR's ROE is -0.10%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, STRR is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check DMTK's competition here
STRR vs MYNZ Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, MYNZ has a market cap of 2.9M. Regarding current trading prices, STRR is priced at $9.45, while MYNZ trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas MYNZ's P/E ratio is -0.13. In terms of profitability, STRR's ROE is -0.10%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, STRR is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MYNZ's competition here
STRR vs SQL Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, STRR is priced at $9.45, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas SQL's P/E ratio is -0.40. In terms of profitability, STRR's ROE is -0.10%, compared to SQL's ROE of +2.74%. Regarding short-term risk, STRR is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check SQL's competition here
STRR vs AWH Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, STRR is priced at $9.45, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas AWH's P/E ratio is -0.09. In terms of profitability, STRR's ROE is -0.10%, compared to AWH's ROE of +3.65%. Regarding short-term risk, STRR is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check AWH's competition here
STRR vs INBS Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, STRR is priced at $9.45, while INBS trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas INBS's P/E ratio is -0.18. In terms of profitability, STRR's ROE is -0.10%, compared to INBS's ROE of -1.98%. Regarding short-term risk, STRR is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check INBS's competition here
STRR vs BIAFW Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BIAFW has a market cap of 1.3M. Regarding current trading prices, STRR is priced at $9.45, while BIAFW trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BIAFW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to BIAFW's ROE of -3.85%. Regarding short-term risk, STRR is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check BIAFW's competition here
STRR vs HTGM Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, STRR is priced at $9.45, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas HTGM's P/E ratio is -0.03. In terms of profitability, STRR's ROE is -0.10%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, STRR is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check HTGM's competition here
STRR vs ISPC Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, ISPC has a market cap of 724.3K. Regarding current trading prices, STRR is priced at $9.45, while ISPC trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas ISPC's P/E ratio is -0.06. In terms of profitability, STRR's ROE is -0.10%, compared to ISPC's ROE of -4.96%. Regarding short-term risk, STRR is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ISPC's competition here
STRR vs BIOC Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, STRR is priced at $9.45, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BIOC's P/E ratio is -0.01. In terms of profitability, STRR's ROE is -0.10%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, STRR is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BIOC's competition here
STRR vs PRENW Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, PRENW has a market cap of 274.1K. Regarding current trading prices, STRR is priced at $9.45, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas PRENW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, STRR is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check PRENW's competition here
STRR vs SQLLW Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, STRR is priced at $9.45, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, STRR's ROE is -0.10%, compared to SQLLW's ROE of +2.74%. Regarding short-term risk, STRR is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check SQLLW's competition here
STRR vs TTOO Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, TTOO has a market cap of 11.2K. Regarding current trading prices, STRR is priced at $9.45, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas TTOO's P/E ratio is -0.01. In terms of profitability, STRR's ROE is -0.10%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, STRR is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check TTOO's competition here
STRR vs NDRAW Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, STRR is priced at $9.45, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas NDRAW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to NDRAW's ROE of -4.97%. Regarding short-term risk, STRR is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NDRAW's competition here
STRR vs DHR-PA Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, STRR is priced at $9.45, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, STRR's ROE is -0.10%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, STRR is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check DHR-PA's competition here
STRR vs CHEKZ Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, STRR is priced at $9.45, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to CHEKZ's ROE of -2.26%. Regarding short-term risk, STRR is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CHEKZ's competition here
STRR vs OCDX Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, STRR is priced at $9.45, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas OCDX's P/E ratio is -42.28. In terms of profitability, STRR's ROE is -0.10%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, STRR is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check OCDX's competition here
STRR vs BNGOW Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, STRR is priced at $9.45, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas BNGOW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to BNGOW's ROE of -0.56%. Regarding short-term risk, STRR is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BNGOW's competition here
STRR vs MEUSW Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, STRR is priced at $9.45, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas MEUSW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, STRR is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MEUSW's competition here
STRR vs PRXL Comparison April 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 35.3M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, STRR is priced at $9.45, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -4.57, whereas PRXL's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.10%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, STRR is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check PRXL's competition here